Inhibikase Therapeutics, Inc. (IKT), a biopharmaceutical company with a market capitalization of $189.48 million, has announced the halting of further development of its Parkinson's disease drug, ...

Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as eating ...

A Colorado Springs family hopes to win what they believe would be a landmark legal verdict by proving to jurors next month ...

A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...

U.S. Department of Defense awards $4 million to researchers at OHSU, University of Washington, VA Portland, VA Puget Sound to ...

Stop the Spread. Injecting saline into mouse kidneys did not affect the left or right substantia nigra (top). Injecting fibrils of α-synuclein ablated about half of the dopaminergic neurons (middle ...

In a significant advancement for Parkinson’s Disease (PD) therapy, researchers have developed a targeted nano formulation ...

A novel wireless photothermal DBS nanosystem uses nanoparticles to target and restore damaged neurons in Parkinson’s disease, ...

Past studies on mice found Lag3 binds to alpha-synuclein proteins and spreads Parkinson's disease pathology in neurons. While ...

The goal of the MCBDTP is to train PhD and MD/PhD scientists who will advance research in experimental Pathology and the molecular and cellular basis of disease. The MCBDTP provides a PhD training ...